PharmaCyte Biotech Valuation
Is PMCB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PMCB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PMCB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PMCB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PMCB?
Key metric: As PMCB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PMCB's PE Ratio? | |
|---|---|
| PE Ratio | 2.9x |
| Earnings | US$4.50m |
| Market Cap | US$13.44m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does PMCB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.7x | ||
EGRX Eagle Pharmaceuticals | 1x | n/a | US$11.7m |
ENZN Enzon Pharmaceuticals | 22.8x | n/a | US$5.3m |
DTIL Precision BioSciences | 4.9x | -41.0% | US$49.9m |
SPRO Spero Therapeutics | 18x | 40.4% | US$64.9m |
PMCB PharmaCyte Biotech | 2.9x | n/a | US$13.4m |
Price-To-Earnings vs Peers: PMCB is good value based on its Price-To-Earnings Ratio (2.9x) compared to the peer average (11.7x).
Price to Earnings Ratio vs Industry
How does PMCB's PE Ratio compare vs other companies in the US Biotechs Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 17.0x | 28.4% | |
PMCB PharmaCyte Biotech | 2.9x | n/a | US$13.44m |
ROIV Roivant Sciences | 2x | -46.3% | US$8.60b |
AGIO Agios Pharmaceuticals | 4.7x | -56.7% | US$3.17b |
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 17.0x | 28.4% | |
PMCB PharmaCyte Biotech | 2.9x | n/a | US$13.44m |
Price-To-Earnings vs Industry: PMCB is good value based on its Price-To-Earnings Ratio (2.9x) compared to the US Biotechs industry average (17.1x).
Price to Earnings Ratio vs Fair Ratio
What is PMCB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 2.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PMCB's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Kiniksa Pharmaceuticals International
US$1.5b
A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
KNSA
US$21.28
7D
-0.05%
1Y
33.2%
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$17.12
7D
4.2%
1Y
79.3%